Catalyst Wire Dossier Catalyst Wire Dossier

HLA-A*2402-restricted tumor vessel-specific peptide vaccine

· University of Tokyo
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HLA-A*2402-restricted tumor vessel-specific peptide vaccine, covering 2009-05-07 to 2009-05-07. Get the full timeline:

Most recent: Clinical Trial Update: Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer [Phase 1, Phase 2]

See pricing